Details

Autor(en) / Beteiligte

• AL-BATRAN, Salah-Eddin
• HARTMANN, Joerg Thomas
• SCHUCH, Gunter
• STOEHLMACHER, Jan
• DERIGS, Hans Günter
• HEGEWISCH-BECKER, Susanna
• GROSSMANN, Johannes
• PAULIGK, Claudia
• ATMACA, Akin
• BOKEMEYER, Carsten
• KNUTH, Alexander
• JÄGER, Elke
• PROBST, Stephan
• SCHMALENBERG, Harald
• HOLLERBACH, Stephan
• HOFHEINZ, Ralf
• RETHWISCH, Volker
• SEIPELT, Gernot
• HOMANN, Nils
• WILHELM, Gerhard

Titel

Phase III Trial in Metastatic Gastroesophageal Adenocarcinoma with Fluorouracil, Leucovorin Plus Either Oxaliplatin or Cisplatin: A Study of the Arbeitsgemeinschaft Internistische Onkologie

Ist Teil von

• Journal of clinical oncology, 2008-03, Vol.26 (9), p.1435-1442

Ort / Verlag

Baltimore, MD: American Society of Clinical Oncology

Erscheinungsjahr

2008

Quelle

MEDLINE

Beschreibungen/Notizen

• This study was designed to compare fluorouracil, leucovorin, and oxaliplatin with fluorouracil, leucovorin, and cisplatin in patients with advanced gastric cancer. Patients with previously untreated advanced adenocarcinoma of the stomach or esophagogastric junction were randomly assigned to receive either fluorouracil 2,600 mg/m(2) via 24-hour infusion, leucovorin 200 mg/m(2), and oxaliplatin 85 mg/m(2) (FLO) every 2 weeks or fluorouracil 2,000 mg/m(2) via 24-hour infusion, leucovorin 200 mg/m(2) weekly, and cisplatin 50 mg/m(2) every 2 weeks (FLP). The primary end point was progression-free survival (PFS). Two hundred twenty patients (median age, 64 years; metastatic, 94%) were randomly assigned. FLO was associated with significantly less (any grade) anemia (54% v 72%), nausea (53% v 70%), vomiting (31% v 52%), alopecia (22% v 39%), fatigue (19% v 34%), renal toxicity (11% v 34%), thromboembolic events (0.9% v 7.8%), and serious adverse events related to the treatment (9% v 19%). FLP was associated with significantly less peripheral neuropathy (22% v 63%). There was a trend toward improved median PFS with FLO versus FLP (5.8 v 3.9 months, respectively; P = .077) and no significant difference in median overall survival (10.7 v 8.8 months, respectively). However, in patients older than 65 years (n = 94), treatment with FLO resulted in significantly superior response rates (41.3% v 16.7%; P = .012), time to treatment failure (5.4 v 2.3 months; P < .001), and PFS (6.0 v 3.1 month; P = .029) and an improved OS (13.9 v 7.2 months) as compared with FLP, respectively. FLO reduced toxicity as compared with FLP. In older adult patients, FLO also seemed to be associated with improved efficacy.